Growth hormone (GH) has been the standard therapy for over 60 years for the treatment of children with growth disorders (1), and since 1985 in the form of recombinant human growth hormone (rhGH, somatropin) (2). This evidence concerns the gene GH1 and hereditary endocrine growth disease.